p53 expression, p53 and Ha-ras mutation and telomerase activation during nitrosamine-mediated hamster pouch carcinogenesis

被引:47
|
作者
Chang, KW
Sarraj, S
Lin, SC
Tsai, PI
Solt, D [1 ]
机构
[1] Northwestern Univ, Dept Pathol, Chicago, IL 60611 USA
[2] Natl Yang Ming Univ, Fac Dent, Taipei 112, Taiwan
[3] Natl Yang Ming Univ, Inst Oral Biol, Taipei 112, Taiwan
关键词
D O I
10.1093/carcin/21.7.1441
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Squamous cell carcinomas (SCC) induced in hamster buccal pouch (HBP) by 22 weeks of topical N-methyl-N-benzylnitrosamine (MBN) treatment (twice-weekly, 10 mg MBN/ml propylene glycol) were evaluated for: (i) altered expression of p53 using immunohistochemistry (IHC); (ii) mutations in T-Ta-Pas and p53 using PCR/single strand conformation polymorphism (SSCP); (iii) telomerase activity using the telomerase repeat amplification protocol (TRAP), Precancerous lesions were also evaluated using p53 IHC. Hamsters mere killed for lesion analysis at either 3 days (group A, eight hamsters, 89 carcinomas) or 7 weeks (group B, six hamsters, 105 carcinomas) following the final MBN application, Between 3 days and 7 weeks post-treatment the proportion of tumors exhibiting p53 IHC activity (at least 10% of nuclei stained using D07 antibodies for detection of both mutant and wild-type p53) fell from 91 to 50%. However, during this same posttreatment period the frequency of tumors analyzed exhibiting confirmed sequence alterations in the conserved exons (E5-E8) of p53 remained constant (5/15 = 33% in group A versus 14/45 = 31% in group B), Heightened expression of wild-type p53 resulting from DNA damage in the immediate post-treatment period is likely to have contributed to the high proportion of group A tumors exhibiting p53 INC activity. Nearly 80% of the identified p53 mutations were G-->A and C-->T transitions. The identified p.53 point mutations occurred at or near (within three codons) of the corresponding hot-spot codons (175, 245, 248 and 273) of human oral SCC, The proportion of group A and group B tumors analyzed exhibiting Ha-ras mutations was 1/15 (7%) and 7/45 (16%), respectively. Only four of the observed eight Ha-ras mutations occurred in codons known to result in activation of this gene. Telomerase activation was demonstrated in 11 of 13 group A tumors (85%) and in 23 of 24 (96%) group B tumors analyzed, The alterations in p53, Ha-ras and telomerase activity observed in this HBP-MBN model are similar in many respects to those observed in the analogous human lesions of the head and neck. This model may be particularly useful for development of cancer chemoprevention regimens and multimodality cancer therapies.
引用
收藏
页码:1441 / 1451
页数:11
相关论文
共 50 条
  • [21] P53 EXPRESSION IN THE CARCINOGENESIS IN THE ORAL-MUCOSA
    GIROD, SC
    KRAMER, C
    KNUFERMANN, R
    KRUEGER, GRF
    JOURNAL OF CELLULAR BIOCHEMISTRY, 1994, 56 (04) : 444 - 448
  • [22] p53 immunohistochemical expression: messages in cervical carcinogenesis
    Cheah, PL
    Looi, LM
    PATHOLOGY, 2002, 34 (04) : 326 - 331
  • [23] A unique basal pattern of p53 expression in ulcerative colitis is associated with mutation in the p53 gene
    Noffsinger, AE
    Belli, JM
    Miller, MA
    Fenoglio-Preiser, CM
    HISTOPATHOLOGY, 2001, 39 (05) : 482 - 492
  • [24] p53 deficiency provokes urothelial proliferation and synergizes with activated Ha-ras in promoting urothelial tumorigenesis
    Gao, J
    Huang, HY
    Pak, J
    Cheng, J
    Zhang, ZT
    Shapiro, E
    Pellicer, A
    Sun, TT
    Wu, XR
    ONCOGENE, 2004, 23 (03) : 687 - 696
  • [25] RAS-INDUCED HYPERPLASIA OCCURS WITH MUTATION OF P53, BUT ACTIVATED RAS AND MYC TOGETHER CAN INDUCE CARCINOMA WITHOUT P53 MUTATION
    LU, X
    PARK, SH
    THOMPSON, TC
    LANE, DP
    CELL, 1992, 70 (01) : 153 - 161
  • [26] The role of p53 isoforms' expression and p53 mutation status in renal cell cancer prognosis
    Florijan, Marijana Knezovic
    Ozretic, Petar
    Bujak, Maro
    Pezze, Laura
    Ciribilli, Yari
    Kastelan, Zeljko
    Slade, Neda
    Hudolin, Tvrtko
    UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2019, 37 (09) : 578.e1 - 578.e10
  • [27] MUC2, p53 expression, and RAS mutation in colorectal cancer
    Liang, Mei
    Wang, Jiang
    Hackett, Chris
    Bishop, John
    Fenoglio-Preiser, Cecilia
    AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 2007, 128 (04) : 687 - 687
  • [28] P53 gene expression in a hamster cholangiocarcinoma model
    Martin, SA
    Nakeeb, A
    Johnston, SM
    Gusev, Y
    Hruban, RH
    Lillemoe, KD
    Lipsett, PA
    Dooley, WC
    Pitt, HA
    HEPATOLOGY, 1996, 24 (04) : 261 - 261
  • [29] RAS AND p53 EXPRESSION IN HUMAN THYROID CARCINOMA
    李晓曦
    吴惠茜
    赵国华
    王深明
    陈国锐
    ChineseJournalofCancerResearch, 2000, (04) : 296 - 299
  • [30] P53 MUTATION AND PROTEIN ACCUMULATION DURING MULTISTAGE HUMAN ESOPHAGEAL CARCINOGENESIS
    BENNETT, WP
    HOLLSTEIN, MC
    METCALF, RA
    WELSH, JA
    HE, A
    ZHU, SM
    KUSTERS, I
    RESAU, JH
    TRUMP, BF
    LANE, DP
    HARRIS, CC
    CANCER RESEARCH, 1992, 52 (21) : 6092 - 6097